Skip to main content

Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes

Abstract

This systematic review and meta-analysis provides an update on the efficacy and safety of vildagliptin for treatment of type 2 diabetes mellitus (T2DM). We searched MEDLINE, COCHRANE, EMBASE and the drug manufacturer’s website for randomised controlled trials of vildagliptin in patients with T2DM. Sixty-nine studies (28,006 patients) were included in the meta-analysis. Compared with placebo vildagliptin reduced HbA1c (weighted mean difference WMD −0.69 %; 95 % CI −0.83 to −0.56 %; I 2 = 82 %), and it was as effective as other antidiabetic agents (WMD −0.01 %; 95 % CI −0.16 to 0.14 %; I 2 = 93 %), without increasing the risk for hypoglycemia (OR 0.83; 95 % CI 0.59 to 1.16; I 2 = 0 % vs. placebo, and OR 0.19; 95 % CI 0.15 to 0.24; I 2 = 78 % versus active comparators). However, it was associated with an increase in the incidence of arthralgia compared with other comparators (OR 1.23; 95 % CI 1.02 to 1.48; I 2 = 0 %). On the contrary, vildagliptin did not increase the incidence of pancreatitis (OR 0.97; 95 % CI 0.37 to 2.53; I 2 = 0 %), serious adverse events (OR 0.98; 95 % CI 0.88 to 1.09; I 2 = 0 %) or death (OR 1.10, 95 % CI 0.75 to 1.61; I 2 = 0 %). Finally, odds ratio (OR) for heart failure, and overall cardiovascular and cerebrovascular events was 0.77 (95 % CI 0.46 to 1.30; I 2 = 0 %) and 0.91 (95 % CI 0.73 to 1.14; I 2 = 0 %), respectively. Vildagliptin is an effective and safe therapeutic option for patients with T2DM, both as monotherapy and as add-on treatment.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

References

  1. 1.

    International Diabetes Federation Diabetes Atlas (Sixth edition). https://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Accessed 17.11.2015

  2. 2.

    S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, D.R. Matthews, Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58(3), 429–442 (2015)

    PubMed  Article  Google Scholar 

  3. 3.

    H. Park, C. Park, Y. Kim, K.L. Rascati, Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann. Pharmacother. 46(11), 1453–1469 (2012)

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    L. Cai, Y. Cai, Z.J. Lu, Y. Zhang, P. Liu, The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J. Clin. Pharm. Ther. 37(4), 386–398 (2012)

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    A. Schweizer, S. Dejager, J.E. Foley, A. Couturier, M. Ligueros-Saylan, W. Kothny, Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes. Metab. 12(6), 485–494 (2010)

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    J. Higgins, S. Green. Missing standard deviations. In: Cochrane Handbook for Systematic Reviews of Interventions. p. 485. (2008)

  7. 7.

    M.J. Sweeting, A.J. Sutton, P.C. Lambert, What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat. Med. 23(9), 1351–1375 (2004)

    PubMed  Article  Google Scholar 

  8. 8.

    J. Higgins, S. Green. Identifying and measuring heterogeneity. In: Cochrane Handbook for Systematic Reviews of Interventions. p. 277. (2008)

  9. 9.

    J. Rosenstock, S.W. Kim, M.A. Baron, R.P. Camisasca, F. Cressier, A. Couturier, S. Dejager, Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes. Metab. 9(2), 175–185 (2007)

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    D.A. D’Alessio, A.M. Denney, L.M. Hermiller, R.L. Prigeon, J.M. Martin, W.G. Tharp, M.L. Saylan, Y. He, B.E. Dunning, J.E. Foley, R.E. Pratley, Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 94(1), 81–88 (2009)

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  11. 11.

    M. Diamant, M. Poelma, D.L. Goede, L.W. Van Golen, R.E. Van Genugten, E.M. Eekhoff, A. Schweizer, R.J. Heine, J.E. Foley, G. Nijpels, M.C. Bunck. One-year vildagliptin, compared to placebo, treatment does not affect markers of bone resorption and calcium homeostasis in drug-naive patients with type 2 diabetes and mild hyperglycemia. Paper presented at the The American Diabetes Association 70th Annual Scientific Sessions, Orlando, Florida

  12. 12.

    Y. Su, Y.L. Su, L.F. Lv, L.M. Wang, Q.Z. Li, Z.G. Zhao, Randomized controlled clinical trial of a combination therapy of vildagliptin plus an alpha-glucosidase inhibitor for patients with type II diabetes mellitus. Exp Ther Med 7(6), 1752–1756 (2014)

    CAS  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Y. Su, Y.L. Su, L.F. Lv, L.M. Wang, Q.Z. Li, Z.G. Zhao, A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus. Exp Ther Med 7(4), 799–803 (2014)

    CAS  PubMed  PubMed Central  Google Scholar 

  14. 14.

    M. Takihata, A. Nakamura, Y. Terauchi, Comparative study of three DPP-4 inhibitors, namely sitagliptin, vildagliptin, and alogliptin, in Japanese type 2 diabetic patients: The COSVA randomized, controlled trial. Diabetes 63, A264 (2014)

    Google Scholar 

  15. 15.

    C.J. Li, Q. Yu, P. Yu, Q.M. Zhang, M. Ding, X.J. Liu, D.M. Yu, Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 122(8), 469–476 (2014)

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    T. Forst, M. Dworak, C. Berndt-Zipfel, A. Loffler, I. Klamp, M. Mitry, A. Pfutzner, Effect of vildagliptin on postprandial proinsulin processing in the beta-cell of patients with type 2 diabetes mellitus. Diabetes 62, A568 (2013)

    Google Scholar 

  17. 17.

    T. Forst, M. Dworak, C. Berndt-Zipfel, A. Loffler, I. Klamp, M. Mitry, A. Pfutzner, Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the beta cell of patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 15(6), 576–579 (2013)

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    C. Filozof, Corrigendum to A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet. Med. 30(5), 632 (2013)

    Article  Google Scholar 

  19. 19.

    G. Derosa, P.D. Ragonesi, A. Carbone, E. Fogari, A. D’Angelo, A.F. Cicero, P. Maffioli, Evaluation of the positive effects on insulin-resistance and beta-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. Pharmacol. Res. 73, 20–26 (2013)

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    B. Bhandare, V. Satyanarayana, J. Adhikary, A comparative study to evaluate the efficacy and safety of Vildagliptin as an add-on therapy to a low-dose Metformin vs an uptitration of Metformin in type 2 DM patients. Int. J. Pharm. Sci. Rev. Res. 22(2), 116–120 (2013)

    Google Scholar 

  21. 21.

    C. Berndt-Zipfel, G. Michelson, I. Klamp, M. Mitry, A. Pfutzner, T. Forst, Vildagliptin in addition to metformin improves retinal arteriolar wall to lumen ratio and erythrocyte flexibility in patients with type 2 diabetes mellitus. Diabetes 62, A156–A157 (2013)

    Google Scholar 

  22. 22.

    C. Berndt-Zipfel, G. Michelson, M. Dworak, M. Mitry, A. Loffler, A. Pfutzner, T. Forst, Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus—results from an exploratory study. Cardiovasc. Diabetol. 12(1), 59 (2013)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    M. Barbieri, M.R. Rizzo, R. Marfella, V. Boccardi, A. Esposito, A. Pansini, G. Paolisso, Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 227(2), 349–354 (2013)

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    M. Abe, Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis. Blood Purif. 34(3–4), 261 (2013)

    Google Scholar 

  25. 25.

    I. Zografou, C. Sampanis, A. Papageorgiou, B. Nikolaidou, P. Doukelis, D. Papadopoulou, M. Doumas, S. Douma, The combination therapy with metformin and vildagliptin decreases lymphocytes count in patients with type 2 diabetes mellitus. Diabetes 61, A600 (2012)

    Google Scholar 

  26. 26.

    M.R. Rizzo, M. Barbieri, R. Marfella, G. Paolisso, Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 35(10), 2076–2082 (2012)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    C. Pan, X. Xing, P. Han, S. Zheng, J. Ma, J. Liu, X. Lv, J. Lu, G. Bader, Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 14(8), 737–744 (2012)

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    V. Lukashevich, M. Wang, S. Del Prato, M. Araga, W. Kothny, Vildagliptin efficacy and safety in patients with type 2 diabetes inadequately controlled on dual metformin plus sulfonylurea therapy. Diabetologia 55, S353 (2012)

    Google Scholar 

  29. 29.

    V. Lukashevich, P. Kozlovski, J. Foley, W. Kothny, Vildagliptin combined with insulin reduces HBA1C without increasing risk of hypoglycemia and weight gain in patients with type 2 diabetes mellitus. Diabetes 61, A254 (2012)

    Google Scholar 

  30. 30.

    P. Kozlovski, J. Foley, Q. Shao, V. Lukashevich, W. Kothny, Improved glycaemic control without increased hypoglycaemia incidence and weight gain with insulin-vildagliptin combination therapy in Asian patients with type 2 diabetes. Diabetologia 55, S355 (2012)

    Google Scholar 

  31. 31.

    W. Kothny, M. Wang, Q. Shao, P.H. Groop, V. Lukashevich, One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes mellitus and moderate or severe renal insufficiency. Diabetes 61, A253 (2012)

    Google Scholar 

  32. 32.

    W. Kothny, Q. Shao, P.H. Groop, V. Lukashevich, One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes. Metab. 14(11), 1032–1039 (2012)

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    W. Kothny, P. Kozlovski, J. Foley, Q. Shao, V. Lukashevich, Vildagliptin added to once or twice daily insulin regimens improves glycaemic control without increasing risk of hypoglycaemia and weight gain in patients with type 2 diabetes. Diabetologia 55, S354 (2012)

    Google Scholar 

  34. 34.

    N.H. Kim, Y.A. Sung, C.W. Ahn, S.W. Park, S. Lim, C.H. Kim, D.S. Kim, Y.G. Shin, K.J. Ahn, J.H. Kim, S.H. Baik, Efficacy and safety of add-on vildagliptin to metformin in comparison to uptitrating metformin therapy. Diabetes 61, A297 (2012)

    Google Scholar 

  35. 35.

    H. Gilet, J.B. Gruenberger, G. Bader, M. Viala-Danten, Demonstrating the burden of hypoglycemia on patients’ quality of life in diabetes clinical trials: measurement considerations for hypoglycemia. Value Health 15(8), 1036–1041 (2012)

    PubMed  Article  Google Scholar 

  36. 36.

    J. Foley, P. Kozlovski, V. Lukashevich, W. Kothny, Vildagliptin improves a chronic effect on beta cell function when added to insulin therapy. Diabetologia 55, S355 (2012)

    Google Scholar 

  37. 37.

    G. Derosa, P.D. Ragonesi, A. Carbone, E. Fogari, A. D’Angelo, A.F. Cicero, P. Maffioli, Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin. Pharmacother. 13(18), 2581–2591 (2012)

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    G. Derosa, P.D. Ragonesi, A. Carbone, E. Fogari, L. Bianchi, A. Bonaventura, D. Romano, A.F. Cicero, P. Maffioli, Vildagliptin added to metformin on beta-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. Diabetes 61, A596 (2012)

    Google Scholar 

  39. 39.

    G. Derosa, P.D. Ragonesi, A. Carbone, E. Fogari, L. Bianchi, A. Bonaventura, D. Romano, A.F. Cicero, P. Maffioli, Vildagliptin added to metformin on beta-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther 14(6), 475–484 (2012)

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    M.C. Bunck, M. Poelma, E.M. Eekhoff, A. Schweizer, R.J. Heine, G. Nijpels, J.E. Foley, M. Diamant, Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. J Diabetes 4(2), 181–185 (2012)

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    V. Lukashevich, A. Schweizer, Q. Shao, P.H. Groop, W. Kothny, Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes. Metab. 13(10), 947–954 (2011)

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    V. Lukashevich, A. Schweizer, J. Foley, Q. Shao, P.H. Groop, W. Kothny, Efficacy of vildagliptin therapy in combination with insulin in patients with type 2 diabetes and severe renal impairment. Diabetologia 54, S332–S333 (2011)

    Google Scholar 

  43. 43.

    W. Kothny, A. Schweizer, R. Naik, P.H. Groop, Q. Shao, V. Lukashevich, Comparison of vildagliptin with placebo in a 24-week study of 221 patients with type 2 diabetes and severe renal impairment (eGFR < 30). Diabetologia 54, S332 (2011)

    Google Scholar 

  44. 44.

    H.J. Jeon, T.K. Oh, Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients. Diabetes Metab J 35(5), 529–535 (2011)

    PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    M. Ito, M. Abe, K. Okada, H. Sasaki, N. Maruyama, M. Tsuchida, T. Higuchi, F. Kikuchi, M. Soma, The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr. J. 58(11), 979–987 (2011)

    CAS  PubMed  Article  Google Scholar 

  46. 46.

    J.B. Gruenberger, H. Gilet, L. Esteve, M. Viala-Danten, Association of patient-reported hypoglycemia with health-related quality of life (HRQL) in type 2 diabetes (T2D) patients: results from a clinical trial. Diabetes 60, A549 (2011)

    Article  Google Scholar 

  47. 47.

    J.E. Foley, M.C. Bunck, D.L. Moller-Goede, M. Poelma, G. Nijpels, E.M. Eekhoff, A. Schweizer, R.J. Heine, M. Diamant, Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 54(8), 1985–1991 (2011)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. 48.

    D.R. Matthews, S. Dejager, B. Ahren, V. Fonseca, E. Ferrannini, A. Couturier, J.E. Foley, B. Zinman, Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes. Metab. 12(9), 780–789 (2010)

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    M. Kikuchi, M. Haneda, D. Koya, K. Tobe, Y. Onishi, A. Couturier, N. Mimori, Y. Inaba, M. Goodman, Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 89(3), 216–223 (2010)

    CAS  PubMed  Article  Google Scholar 

  50. 50.

    Y. Iwamoto, A. Kashiwagi, N. Yamada, S. Terao, N. Mimori, M. Suzuki, H. Tachibana, Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes. Metab. 12(8), 700–708 (2010)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. 51.

    C. Filozof, S. Schwartz, J.E. Foley, Effect of vildagliptin as add-on therapy to a low-dose metformin. World J. Diabetes 1(1), 19–26 (2010)

    PubMed  PubMed Central  Article  Google Scholar 

  52. 52.

    C. Filozof, J.F. Gautier, A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet. Med. 27(3), 318–326 (2010)

    CAS  PubMed  Article  Google Scholar 

  53. 53.

    M.A. Banerji, D. Purkayastha, B.H. Francis, Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study. Diabetes Res. Clin. Pract. 90(2), 182–190 (2010)

    CAS  PubMed  Article  Google Scholar 

  54. 54.

    B. Ahren, J.E. Foley, E. Ferrannini, D.R. Matthews, B. Zinman, S. Dejager, V.A. Fonseca, Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 33(4), 730–732 (2010)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    A. Schweizer, S. Dejager, E. Bosi, Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes. Metab. 11(8), 804–812 (2009)

    CAS  PubMed  Article  Google Scholar 

  56. 56.

    J. Rosenstock, M. Niggli, M. Maldonado-Lutomirsky, Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 11(6), 571–578 (2009)

    CAS  PubMed  Article  Google Scholar 

  57. 57.

    J.J. Meier, M. Vollmer, C. Pennartz, C. Abletshauser, W.E. Schmidt, Efficacy and safety of early combination of vildagliptin and metformin in comparison to placebo in patients with type 2 diabetes. Diabetologia 52(S1), S304 (2009)

    Google Scholar 

  58. 58.

    M. Kikuchi, N. Abe, M. Kato, S. Terao, N. Mimori, H. Tachibana, Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 83(2), 233–240 (2009)

    CAS  PubMed  Article  Google Scholar 

  59. 59.

    M. Goodman, H. Thurston, J. Penman, Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm. Metab. Res. 41(5), 368–373 (2009)

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    B. Francis, D. Purkayastha, M.A. Banerji, Safety of vildagliptin in patients with mild renal impairment and patients with normal renal function: GALIANT study. Can. J. Diabetes 33(3), 288–289 (2009)

    Article  Google Scholar 

  61. 61.

    J.E. Foley, S. Sreenan, Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm. Metab. Res. 41(12), 905–909 (2009)

    CAS  PubMed  Article  Google Scholar 

  62. 62.

    J.E. Foley, S.S. Efficacy, Erratum: safety comparison between the dpp-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm. Metab. Res. 41(12), 909 (2009)

    Article  CAS  Google Scholar 

  63. 63.

    E. Ferrannini, V. Fonseca, B. Zinman, D. Matthews, B. Ahren, S. Byiers, Q. Shao, S. Dejager, Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes. Metab. 11(2), 157–166 (2009)

    CAS  PubMed  Article  Google Scholar 

  64. 64.

    E. Bosi, F. Dotta, Y. Jia, M. Goodman, Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 11(5), 506–515 (2009)

    CAS  PubMed  Article  Google Scholar 

  65. 65.

    G. Bolli, F. Dotta, L. Colin, B. Minic, M. Goodman, Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes. Metab. 11(6), 589–595 (2009)

    CAS  PubMed  Article  Google Scholar 

  66. 66.

    L. Blonde, S. Dagogo-Jack, M.A. Banerji, R.E. Pratley, A. Marcellari, R. Braceras, D. Purkayastha, M. Baron, Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial-a primary care, type 2 diabetes study. Diabetes Obes. Metab. 11(10), 978–986 (2009)

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    B. Ahren, J. Foley, E. Ferrannini, D. Matthews, B. Zinman, S. Dejager, V. Fonseca, Changes in prandial glucagon levels after 2 years treatment with vildagliptin or glimepiride. Diabetologia 52(S1), S314 (2009)

    Google Scholar 

  68. 68.

    W.A. Scherbaum, A. Schweizer, A. Mari, P.M. Nilsson, G. Lalanne, Y. Wang, B.E. Dunning, J.E. Foley, Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes. Metab. 10(11), 1114–1124 (2008)

    CAS  PubMed  Article  Google Scholar 

  69. 69.

    W.A. Scherbaum, A. Schweizer, A. Mari, P.M. Nilsson, G. Lalanne, S. Jauffret, J.E. Foley, Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes. Metab. 10(8), 675–682 (2008)

    CAS  PubMed  Article  Google Scholar 

  70. 70.

    C. Pan, W. Yang, J.P. Barona, Y. Wang, M. Niggli, P. Mohideen, Y. Wang, J.E. Foley, Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet. Med. 25(4), 435–441 (2008)

    PubMed  Article  CAS  Google Scholar 

  71. 71.

    A. Mari, W.A. Scherbaum, P.M. Nilsson, G. Lalanne, A. Schweizer, B.E. Dunning, S. Jauffret, J.E. Foley, Characterization of the influence of vildagliptin on model-assessed beta-cell function in patients with type 2 diabetes and mild hyperglycemia. J. Clin. Endocrinol. Metab. 93(1), 103–109 (2008)

    CAS  PubMed  Article  Google Scholar 

  72. 72.

    B. Goke, K. Hershon, D. Kerr, A. Calle Pascual, A. Schweizer, J. Foley, Q. Shao, S. Dejager, Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm. Metab. Res. 40(12), 892–895 (2008)

    CAS  PubMed  Article  Google Scholar 

  73. 73.

    A.J. Garber, J.E. Foley, M.A. Banerji, P. Ebeling, S. Gudbjornsdottir, R.P. Camisasca, A. Couturier, M.A. Baron, Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes. Metab. 10(11), 1047–1056 (2008)

    CAS  PubMed  Article  Google Scholar 

  74. 74.

    G. Bolli, F. Dotta, E. Rochotte, S.E. Cohen, Efficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes. Metab. 10(1), 82–90 (2008)

    CAS  PubMed  Google Scholar 

  75. 75.

    A. Schweizer, A. Couturier, J.E. Foley, S. Dejager, Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet. Med. 24(9), 955–961 (2007)

    CAS  PubMed  Article  Google Scholar 

  76. 76.

    F.X. Pi-Sunyer, A. Schweizer, D. Mills, S. Dejager, Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res. Clin. Pract. 76(1), 132–138 (2007)

    CAS  PubMed  Article  Google Scholar 

  77. 77.

    A.J. Garber, A. Schweizer, M.A. Baron, E. Rochotte, S. Dejager, Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes. Metab. 9(2), 166–174 (2007)

    CAS  PubMed  Article  Google Scholar 

  78. 78.

    V. Fonseca, A. Schweizer, D. Albrecht, M.A. Baron, I. Chang, S. Dejager, Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50(6), 1148–1155 (2007)

    CAS  PubMed  Article  Google Scholar 

  79. 79.

    S. Dejager, S. Razac, J.E. Foley, A. Schweizer, Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm. Metab. Res. 39(3), 218–223 (2007)

    CAS  PubMed  Article  Google Scholar 

  80. 80.

    E. Bosi, R.P. Camisasca, C. Collober, E. Rochotte, A.J. Garber, Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30(4), 890–895 (2007)

    CAS  PubMed  Article  Google Scholar 

  81. 81.

    B. Ahren, G. Pacini, A. Tura, J.E. Foley, A. Schweizer, Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm. Metab. Res. 39(11), 826–829 (2007)

    CAS  PubMed  Article  Google Scholar 

  82. 82.

    R.E. Pratley, S. Jauffret-Kamel, E. Galbreath, D. Holmes, Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm. Metab. Res. 38(6), 423–428 (2006)

    CAS  PubMed  Article  Google Scholar 

  83. 83.

    S. Ristic, S. Byiers, J. Foley, D. Holmes, Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes. Metab. 7(6), 692–698 (2005)

    CAS  PubMed  Article  Google Scholar 

  84. 84.

    B. Ahren, G. Pacini, J.E. Foley, A. Schweizer, Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28(8), 1936–1940 (2005)

    CAS  PubMed  Article  Google Scholar 

  85. 85.

    B. Ahren, R. Gomis, E. Standl, D. Mills, A. Schweizer, Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27(12), 2874–2880 (2004)

    CAS  PubMed  Article  Google Scholar 

  86. 86.

    B. Ahren, J.E. Foley, S. Dejager, M. Akacha, Q. Shao, G. Heimann, M. Dworak, A. Schweizer, Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities? Diabetes Ther 5(2), 459–469 (2014)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  87. 87.

    M.C. Bunck, M. Poelma, D.L. Goede, L.W. Van Golen, R.E. Van Genugten, E.M. Eekhoff, A. Schweizer, R.J. Heine, J.E. Foley, G. Nijpels, M. Diamant. Beta-cell function and glycemic control following one-year vildagliptin treatment, and after 12-week washout, in drug-naive patients with type 2 diabetes and mild hyperglycemia. Paper presented at the The American Diabetes Association 70th Annual Scientific Sessions, Orlando, Florida

  88. 88.

    W. David Strain, V. Lukashevich, W. Kothny, M.J. Hoellinger, P. Paldanius, INdividualised Treatment targets for EldeRly patients using Vildagliptin Add-on or Lone therapy (INTERVAL) study. Diabetologia 56, S354–S355 (2013)

    Google Scholar 

  89. 89.

    W.L. de Ranitz-Greven, J.W. Beulens, L.B. Hoeks, G. Belle-van Meerkerk, D.H. Biesma, H.W. de Valk, Patients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin. BMC Res Notes 7, 579 (2014)

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  90. 90.

    G. Derosa, A. Bonaventura, L. Bianchi, D. Romano, E. Fogari, A. D’Angelo, P. Maffioli, Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. Metab. Clin. Exp. 63(7), 957–967 (2014)

    CAS  PubMed  Article  Google Scholar 

  91. 91.

    G. Derosa, A. Bonaventura, L. Bianchi, D. Romano, E. Fogari, A. D’Angelo, P. Maffioli, Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with Type 2 diabetes. Diabet. Med. 31(12), 1515–1523 (2014)

    CAS  PubMed  Article  Google Scholar 

  92. 92.

    M. Hassanein, K. Abdallah, A. Schweizer, A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc. Health Risk Manag. 10, 319–326 (2014)

    CAS  PubMed  PubMed Central  Google Scholar 

  93. 93.

    W. Kothny, J. Foley, A. Schweizer, M.S. Rendell, V. Lukashevich, Efficacy of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment. Diabetologia 57, S357–S358 (2014)

    Google Scholar 

  94. 94.

    V. Lukashevich, S.D. Prato, M. Araga, W. Kothny, Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes. Metab. 16(5), 403–409 (2014)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  95. 95.

    P. Maffioli, A. Bonaventura, L. Bianchi, D. Romano, E. Fogari, A. D’Angelo, G. Derosa, Comparison of vildagliptin and glimepiride: effects on glycemic control, fat tolerance, and inflammatory markers in people with type 2 diabetes. Diabetes 63, A277 (2014)

    Google Scholar 

  96. 96.

    M. Odawara, I. Hamada, M. Suzuki, Efficacy and safety of vildagliptin as add-on to metformin in japanese patients with type 2 diabetes mellitus. Diabetes Ther 5(1), 169–181 (2014)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  97. 97.

    H.J. Strotmann, D. Goetze, C. Koch, T. Forst, Vildagliptin versus insulin as add-on therapy to glimepiride in type 2 diabetes mellitus: results from a randomised controlled trial. Diabetologia 1, S364–S365 (2014)

    Google Scholar 

  98. 98.

    G. Ning, W. Wang, L. Li, J. Ma, X. Lv, M. Yang, W. Wang, M. Woloschak, V. Lukashevich, W. Kothny, Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. J. Diabetes (2015). doi:10.1111/1753-0407.12303

    Google Scholar 

  99. 99.

    W. Yang, X. Xing, X. Lv, Y. Li, J. Ma, G. Yuan, F. Sun, W. Wang, M. Woloschak, V. Lukashevich, P. Kozlovski, W. Kothny, Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus. J. Diabetes 7(2), 174–181 (2015)

    PubMed  Article  CAS  Google Scholar 

  100. 100.

    T. Forst, C. Koch, M. Dworak, Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study. Curr. Med. Res. Opin. 31(6), 1079–1084 (2015)

    CAS  PubMed  Article  Google Scholar 

  101. 101.

    A.R. Hong, J. Lee, E.J. Ku, Y. Hwangbo, K.M. Kim, J.H. Moon, S.H. Choi, H.C. Jang, S. Lim, Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): a randomized trial. Diabetes Res. Clin. Pract. 109(1), 141–148 (2015)

    CAS  PubMed  Article  Google Scholar 

  102. 102.

    M. Macauley, K.G. Hollingsworth, F.E. Smith, P.E. Thelwall, A. Al-Mrabeh, A. Schweizer, J.E. Foley, R. Taylor, Effect of vildagliptin on hepatic steatosis. J. Clin. Endocrinol. Metab. 100(4), 1578–1585 (2015)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  103. 103.

    Y. Takeshita, T. Takamura, Y. Kita, T. Otoda, K.I. Kato, H. Wakakuri, M. Yamada, H. Misu, Y. Matsushima, S. Kaneko, Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study. J. Diabetes Investig. 6(2), 192–200 (2015)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  104. 104.

    I. Zografou, C. Sampanis, E. Gkaliagkousi, F. Iliadis, A. Papageorgiou, P. Doukelis, K. Vogiatzis, S. Douma, Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus. Hormones 14(1), 118–125 (2015)

    PubMed  Google Scholar 

  105. 105.

    A. Strozik, A. Steposz, M. Basiak, M. Drozdz, B. Okopien, Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus. Pharmacol. Rep. 67(1), 24–31 (2015)

    CAS  PubMed  Article  Google Scholar 

  106. 106.

    G. Ning, L. Li, J. Ma, X. Lv, M. Yang, W. Wang, M. Woloschak, V. Lukashevich, W. Kothny, Vildagliptin as add-on to insulin improves glycaemic control without increased risk of hypoglycaemia in Asian (predominantly Chinese) patients with type 2 diabetes mellitus. Diabetologia 57, S330 (2014)

    Google Scholar 

  107. 107.

    CLAF237A1303. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2490. Accessed 18 June 2015

  108. 108.

    CLAF237A2205. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1475

  109. 109.

    CLAF237A2329. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2297

  110. 110.

    CLAF237A23118. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=9563. Accessed 18 June 2015

  111. 111.

    CLAF237AFR03. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=7283. Accessed 18 June 2015

  112. 112.

    CLAF237B2224. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=9923. Accessed 18 June 2015

  113. 113.

    CLAF237A23155. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=11764. Accessed 18 June 2015

  114. 114.

    CLAF237B2201. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=4586. Accessed 18 June 2015

  115. 115.

    CLAF237A23138. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=4599. Accessed 18 June 2015

  116. 116.

    W. Kothny, V. Lukashevich, J.E. Foley, M.S. Rendell, A. Schweizer, Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial. Diabetologia 58(9), 2020–2026 (2015)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  117. 117.

    CLAF237A23154. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=10803. Accessed 18 June 2015

  118. 118.

    C.J. Li, X.J. Liu, L. Bai, Q. Yu, Q.M. Zhang, P. Yu, D.M. Yu, Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol. Metab. Syndr. 6(1), 69 (2014)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  119. 119.

    J. Rosenstock, M.A. Baron, S. Dejager, D. Mills, A. Schweizer, Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30(2), 217–223 (2007)

    CAS  PubMed  Article  Google Scholar 

  120. 120.

    J. Rosenstock, M.A. Baron, S. Dejager, D. Mills, A. Schweizer, Erratum: comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial (Diabetes Care (2007) 30 (217–223)). Diabetes Care 30(5), 1330 (2007)

    CAS  Google Scholar 

  121. 121.

    W. Kothny, J. Foley, P. Kozlovski, Q. Shao, B. Gallwitz, V. Lukashevich, Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 15(3), 252–257 (2013)

    CAS  PubMed  Article  Google Scholar 

  122. 122.

    A. Strozik, A. Steposz, B. Okopien, Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus. Diabetes 62, A668 (2013)

    Google Scholar 

  123. 123.

    I. Zografou, C. Sampanis, A. Papageorgiou, B. Nikolaidou, P. Doukelis, D. Papadopoulou, M. Doumas, S. Douma, The effect of vildagliptin on arterial stiffness in drug naive patients with type 2 diabetes mellitus. Diabetes 62, A596 (2013)

    Google Scholar 

  124. 124.

    M. Haidinger, J. Werzowa, M. Hecking, M. Antlanger, G. Stemer, J. Pleiner, C. Kopecky, J.J. Kovarik, D. Doller, G. Pacini, M.D. Saemann, Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation-a randomized, double-blind, placebo-controlled trial. Am. J. Trans. 14(1), 115–123 (2014)

    CAS  Article  Google Scholar 

  125. 125.

    M. Haidinger, J. Werzowa, M. Hecking, G. Stemer, J. Pleiner, C. Kopecky, G. Pacini, M. Antlanger, M.D. Saemann, Vildagliptin in new-onset diabetes after kidney transplantation is safe and efficencient-results from the viennavinodat trial. Nephrol. Dial. Trans. 28, i77 (2013)

    Article  Google Scholar 

  126. 126.

    M. Haidinger, J. Werzowa, M. Hecking, G. Pacini, M. Antlanger, J. Kovarik, Efficacy and safety of vildagliptin in newly diagnosed diabetes after kidney transplantation: results from the Vienna VINODAT trial. Wien. Klin. Wochenschr. 25, S19–S20 (2013)

    Google Scholar 

  127. 127.

    M. Haidinger, J. Werzowa, H.C. Voigt, J. Pleiner, G. Stemer, M. Hecking, D. Doller, W.H. Horl, T. Weichhart, M.D. Saemann, A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation. Trials 11, 91 (2010)

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  128. 128.

    W.D. Strain, V. Lukashevich, W. Kothny, M.J. Hoellinger, P.M. Paldanius, Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 382(9890), 409–416 (2013)

    CAS  PubMed  Article  Google Scholar 

  129. 129.

    CLAF237A23138E1. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=5923. Accessed 18 June 2015

  130. 130.

    FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm (2015). Accessed 29 August 2015

  131. 131.

    J.B. Green, M.A. Bethel, P.W. Armstrong, J.B. Buse, S.S. Engel, J. Garg, R. Josse, K.D. Kaufman, J. Koglin, S. Korn, J.M. Lachin, D.K. McGuire, M.J. Pencina, E. Standl, P.P. Stein, S. Suryawanshi, F. Van de Werf, E.D. Peterson, R.R. Holman, Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. (2015). doi:10.1056/NEJMoa1501352

    PubMed Central  Google Scholar 

  132. 132.

    B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, B. Hirshberg, P. Ohman, R. Frederich, S.D. Wiviott, E.B. Hoffman, M.A. Cavender, J.A. Udell, N.R. Desai, O. Mosenzon, D.K. McGuire, K.K. Ray, L.A. Leiter, I. Raz, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369(14), 1317–1326 (2013)

    CAS  PubMed  Article  Google Scholar 

  133. 133.

    W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris, A.T. Perez, P.R. Fleck, C.R. Mehta, S. Kupfer, C. Wilson, W.C. Cushman, F. Zannad, Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369(14), 1327–1335 (2013)

    CAS  PubMed  Article  Google Scholar 

  134. 134.

    D.R. Matthews, A. Tsapas, Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. Diabetes Vasc. Dis. Res. 5(3), 216–218 (2008)

    Article  Google Scholar 

  135. 135.

    K. Krum, V. Lukashevich, G.B. Bolli, P. Kozlovski, W. Kothny, P. Ponikowski. No Significant Difference in Risk of Heart Failure Hospitalization with Vildagliptin in Diabetic Patients with Systolic Chronic Heart Failure: VIVIDD. Paper presented at the The American Diabetes Association 74th Annual Scientific Sessions, San Francisco, California, June 13–17

  136. 136.

    J. McMurray. The vildagliptin in ventricular dysfunction diabetes (VIVIDD) trial. Paper presented at the Heart Failure Congress, Lisbon, Portugal, May 25–28

  137. 137.

    M. Evans, G. McInnes, M. Stumvoll, S. Del Prato, A. Schweizer, Q. Shao, V. Lukashevich, W. Kothny, Assessment of heart failure risk with vildagliptin in diabetic patients: pooled analysis of safety data from approximately 17,000 patients. Diabetologia 57(1 SUPPL. 1), S361 (2014)

    Google Scholar 

  138. 138.

    M. Monami, I. Dicembrini, E. Mannucci, Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr. Metab. Cardiovasc. Dis. 24(7), 689–697 (2014)

    CAS  PubMed  Article  Google Scholar 

  139. 139.

    G. McInnes, M. Evans, S. Del Prato, M. Stumvoll, A. Schweizer, V. Lukashevich, Q. Shao, W. Kothny. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17000 patients. Diabetes Obes Metab (2015)

  140. 140.

    Guidance for Industry Diabetes Mellitus—Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. In: Services, U.S.D.o.H.a.H. (ed.) Federal Register: The daily journal of the United States Government, vol. 18 June 2015. (Food and Drug Administration, 2008)

Download references

Acknowledgement

This work was partly supported by Novartis Pharmaceuticals Corporation. All authors participated in the development and writing of the article, approved the final manuscript for publication, and take full responsibility for the content of the article.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Apostolos Tsapas.

Ethics declarations

Conflicts of interest

A.T. has received lecture or consultancy fees from AstraZeneca, Boehringer Ingelheim and MSD, and research support from Novartis, Novo Nordisk and Sanofi. E.A. has received research support from Novartis. The remaining authors declare no competing interests.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 670 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bekiari, E., Rizava, C., Athanasiadou, E. et al. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine 52, 458–480 (2016). https://doi.org/10.1007/s12020-015-0841-1

Download citation

Keywords

  • Vildagliptin
  • DPP-4 inhibitors
  • Systematic review
  • Meta-analysis